A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
An article from
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
Published May 12, 2026
Tumors positive for estrogen receptors are the most common subtype of breast cancer.
Douglas Olivares via Getty Images
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
Astellas treatment offers new hope to a devastated rare disease community
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
FDA to reconsider treatment for rare cancer after its surprise rejection
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
BeOne wins FDA approval in lymphoma race
AstraZeneca follows Merck with Phase 3 win in bladder cancer
FDA revisits a rare cancer treatment it rejected a few months ago
Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure
Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
